NCT03330847 2026-03-10To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.AstraZenecaPhase 2 Active not recruiting273 enrolled 22 charts
NCT03801369 2026-02-25AMTEC IIT: Phase 2 Multiarm Study in TNBCOHSU Knight Cancer InstitutePhase 2 Terminated24 enrolled 16 charts